"Yttrium Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
| Descriptor ID |
D015021
|
| MeSH Number(s) |
D01.268.558.975.500.800 D01.268.956.890.500.800 D01.496.749.960 D01.496.943.800 D01.552.550.975.500.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Yttrium Radioisotopes".
Below are MeSH descriptors whose meaning is more specific than "Yttrium Radioisotopes".
This graph shows the total number of publications written about "Yttrium Radioisotopes" by people in this website by year, and whether "Yttrium Radioisotopes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Yttrium Radioisotopes" by people in Profiles.
-
Hong K, Akinwande O, Bodei L, Chamarthy MR, Devlin PM, Elman S, Ganguli S, Kennedy AS, Koo SJ, Ouhib Z, Padia SA, Salem R, Selwyn RG, Yashar CM, Yoo DC, Zaki BI, Hartford AC, Trimmer CK. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. Brachytherapy. 2021 May-Jun; 20(3):497-511.
-
Dou S, Wang Y, Barton B, Chen L, Rusckowski M, Shultz LD, Greiner DL, Liu G. Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach. Nucl Med Biol. 2014 Jan; 41(1):127-31.
-
Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN. Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leuk Lymphoma. 2013 Mar; 54(3):497-502.
-
Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010 Sep; 21(9):1377-84.
-
Borchardt PE, Vriesendorp HM, Freedman RS, Quadri SM. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts. Cancer Biother Radiopharm. 2004 Feb; 19(1):43-51.
-
Lazewatsky J, Ding Y, Onthank D, Silva P, Solon E, Robinson S. Radiation dose to abdominal organs of the mouse due to 90Y in the urinary bladder. Cancer Biother Radiopharm. 2003 Jun; 18(3):413-9.
-
Liu CB, Liu GZ, Liu N, Zhang YM, He J, Rusckowski M, Hnatowich DJ. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc. Nucl Med Biol. 2003 Feb; 30(2):207-14.